Skip to main content

NCT00915655 - A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years

A Phase II, Open-Label Trial, to Evaluate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Drv/Rtv Once Daily in Treatment-Naive HIV-1 Infected Adolescents Aged Between 12 and < 18 Years


CSR Summary

Not Yet Available


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Darunavir
Product Name
PREZISTA®
Therapeutic Area
Immune System Diseases
Enrollment
12
% Female
66.7%
% White
N/A
Product Class
Antiviral Agent
Sponsor Protocol Number
TMC114-TiDP29-C230
Data Partner
Johnson & Johnson
Condition Studied
HIV Infections
Mean/Median Age (Years)
14.7

Supporting Documentation

Clinical Study Report
Collected Datasets
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.